Cortactin is associated with tumour progression and poor prognosis in prostate cancer and SIRT2 other than HADC6 may work as facilitator in situ

Journal of Clinical Pathology

Volumn 65, Issue 12, 2012, Pages 1088-1096

  Hou, Huilian ^a   Chen, Wei ^a   Zhao, Le ^a   Zuo, Qinqin ^a   Zhang, Guanjun ^a   Zhang, Xuebin ^a   Wang, Hongyan ^a   Gong, Huilin ^a   Li, Xiaofeng ^a   Wang, Min ^a   Wang, Yili ^a   Li, Xu ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CORTACTIN; HISTONE DEACETYLASE 6; PROSTATE SPECIFIC ANTIGEN; SIRTUIN 2;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CANCER TISSUE; CELL SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRANSURETHRAL RESECTION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CORTACTIN; DISEASE PROGRESSION; HISTONE DEACETYLASES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM GRADING; PROGNOSIS; PROSTATE; PROSTATIC NEOPLASMS; SIRTUIN 2; TUMOR MARKERS, BIOLOGICAL;

EID: 84870063661     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2012-200940     Document Type: Article

References (32)

1. Mohler J, Bahnson RR, Boston BJ, et al. Prostate Cancer. J Natl Compr Canc Netw 2010;8:162-200.
2. Beth AJ, Liu WL, Andre BA, et al. Explaining the race difference in prostate cancer stage at diagnosis. Cancer Epidemiol Biomarkers Prev 2008;17:2825-34.
3. Gomella LG, Singh J, Lallas C, et al. Hormone therapy in the management of prostate cancer: evidence-based approaches. Ther Adv Urol 2010;2:171-81.
4. Scott DC, Sun J, Zheng SL. Association of prostate-specific antigen promoter genotype with clinical and histopathologic features of prostate cancer. Cancer Epidemiol Biomarkers Prev 2008;17:2451-7.
5. Drake PM, Cho W, Li BS, et al. Sweetening the pot: adding glycosylation to the biomarker discovery equation. Clin Chem 2010;56:223-36.
6. Ayala I, Baldassarre M, Giacchetti G, et al. Multiple regulatory inputs converge on cortactin to control invadopodia biogenesis and extracellular matrix degradation. J Cell Sci 2008;121:369-78. (Pubitemid 351356708)
7. Weaver AM. Cortactin in tumor invasiveness. Cancer Lett 2008;265:157-66.
8. Radhika V, Onesime D, Ha JH, et al. Galpha13 stimulates cell migration through cortactin-interacting protein Hax-1. J Biol Chem 2004;279:49406-13. (Pubitemid 39625826)
9. Southwood CM, Peppi M, Dryden S, et al. Microtubule deacetylases, SirT2 and HDAC6, in the nervous system. Neurochem Res 2007;32:187-95. (Pubitemid 46238864)
10. Souèek K, Andrés K, Anh DP, et al. Normal and prostate cancer cells display distinct molecular profiles of a-tubulin posttranslational modifications. The Prostate 2006;66:954-65.
11. Borra MT, O'Neill FJ, Jackson MD, et al. Conserved enzymatic production and biological effect of O-acetyl-ADP-ribose by silent information regulator 2-like NAD + -dependent deacetylases. J Biol Chem 2002;277:12632-41. (Pubitemid 34952622)
12. Dong-Anh TA, Marmo TP, Salam AA, et al. HDAC6 deacetylation of tubulin modulates dynamics of cellular adhesions. J Cell Sci 2007;120:1469-79. (Pubitemid 46780039)
13. Sylvia CD, Fatimah AN, James EN, et al. Role for human SIRT2 NAD-Dependent deacetylase activity in control of mitotic exit in the cell cycle. Mol Cell Biol 2003;23:3173-85.
14. Yuliya Z, Christoph B, Letizia C, et al. Regulation of microtubule dynamics by inhibition of the tubulin deacetylase HDAC6. J Cell Sci 2009;122:3531-41.
15. Oser M, Mader CC, Hava G-H, et al. Specific tyrosine phosphorylation sites on cortactin regulate Nck1-dependent actin polymerization in invadopodia. J Cell Sci 2010;123:3662-73.
16. Huang J, Asawa T, Takato T, et al. Cooperative roles of Fyn and cortactin in cell migration of metastatic murine melanoma. J Biol Chem 2003;278:48367-76. (Pubitemid 37523292)
17. Kocher HM, Sandle J, Mirza TA, et al. Ezrin interacts with cortactin to form podosomal rosettes in pancreatic cancer cells. Gut 2009;58:271-84.
18. Li Y, Tondravi M, Liu J, et al. Cortactin potentiates bone metastasis of breast cancer cells. Cancer Res 2001;61:6906-11. (Pubitemid 32896517)
19. Gibcus JH, Mastik MF, Menkema L, et al. Cortactin expression predicts poor survival in laryngeal carcinoma. Brit J Cancer 2008;98:950-5. (Pubitemid 351341606)
20. Liu HS, Lu HH, Lui MT, et al. Detection of copy number amplification of cyclin D1 (CCND1) and cortactin (CTTN) in oral carcinoma and oral brushed samples from areca chewers. Oral Oncol 2009;45:1032-6.
21. Wang GC, Hsieh PS, Hsu HH, et al. Expression of cortactin and survivin in renal cell carcinoma associated with tumor aggressiveness. World J Urol 2009;27:557-63.
22. Chuma M, Sakamoto M, Yasuda J, et al. Overexpression of cortactin is involved in motility and metastasis of hepatocellular carcinoma. J Hepatol 2004;41:629-36. (Pubitemid 39297799)
23. Hsu NY, Yeh KT, Chiang IP, et al. Cortactin overexpression in the esophageal squamous cell carcinoma and its involvement in the carcinogenesis. Dis Esophagus 2008;21:402-8.
24. Hashimoto S, Hirose M, Hashimoto A, et al. Targeting AMAP1 and cortactin binding bearing an atypical src homology 3/proline interface for prevention of breast cancer invasion and metastasis. PNAS 2006;103:7036-41.
25. Tsai WC, Jin JS, Chang WK, et al. Association of cortactin and Fascin-1 expression in gastric adenocarcinoma: correlation with clinicopathological parameters. J Histochem Cytochem 2007;55:955-62.
26. Carrie AF, Evangeline A, Viktor T, et al. The chemopreventive bioflavonoid apigenin inhibits prostate cancer cell motility through the focal adhesion kinase/Src signaling mechanism. Cancer Prev Res 2009;2:830-41.
27. Gibbs A, Schwartzman J, Deng V, et al. Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6. PNAS 2009;106:16663-8.
28. Yilmaz M, Christofori G. Mechanisms of motility in metastasizing cells. Mol Cancer Res 2010;8:629-42.
29. Gao YS, Charlotte CH, Yao TP. The microtubule-associated histone deacetylase 6 (HDAC6) regulates epidermal growth factor receptor (EGFR) endocytic trafficking and degradation. J Biol Chem 2010;285:11219-26.
30. Zhang KH, Wang DM, Song JG. Cortactin is involved in transforming growth factor-b1-induced epithelial-mesenchymal transition in AML-12 cells. Acta Biochim Biophys Sin 2009;41:839-45.
31. Zhang XH, Yuan ZG, Zhang YG, et al. HDAC6 modulates cell motility by altering the acetylation level of cortactin. Mol Cell 2007;27:197-213.
32. Sanchez1 CG, Penfornis P, Oskowitz AZ, et al. Activation of autophagy in mesenchymal stem cells provides tumor stromal support. Carcinogenesis 2011;l32:964-72.